Skip to main content
SpringerLink
Log in

Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review

  • Review
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Al Sarraf M, Fletcher W, Oishi N, Pugh R, Hewlett JS, Balducci L, McCracker J, Padilla F (1982) Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma. A Southwest Oncology Group study. Cancer Treat Rep 66: 31

    Google Scholar 

  2. Anand AJ, Bashey B (1993) Newer insights into cisplatin toxicity. Ann Pharmacother 27: 1519

    Google Scholar 

  3. Baldew GS, McVie JG, Van Der Valk MA, Los G, De Goeij JJM, Vermeulen NPE (1990) Selective reduction in thecis-diamminedichloroplatinum(II) nephrotoxicity by ebselen. Cancer Res 50: 7031

    Google Scholar 

  4. Belt RJ, Himmelstein KJ, Patton TF, Bannister SJ, Sterson LA, Repta AJ (1979) Pharmacokinetics of non protein-bound platinum species following administration ofcis-diamminedichloroplatinum(II). Cancer Treat Rep 63: 1515

    Google Scholar 

  5. Berry JM, Jacobs C, Sikic B, Halsey J, Borch RF (1990) Modification of cisplatin toxicity with diethyldithiocarbamate. J Clin Oncol 8: 1585

    Google Scholar 

  6. Bird JE, Walser MM, Quebbemann AJ (1984) Protective effect of organic cation transport inhibitors oncis-diamminedichloroplatinum-induced nephrotoxicity. J Pharmacol Exp Ther 231: 752

    Google Scholar 

  7. Bird JE, Walser MM, Quebbemann AJ (1985) Protective effect of quinine on nephrotoxicity-induced bycis-diamminedichloroplatinum (abstract). Kidney Int 27: 228

    Google Scholar 

  8. Bitran JD, Desser RK, Billings AA, Kozloff MF, Shapiro CM (1982) Acute nephrotoxicity followingcis-dichlorodiammine-platinum. Cancer 49: 1784

    Google Scholar 

  9. Bodenner DL, Dedon PC, Keng PC, Katz JC, Borch RF (1986) Selective protection againstcis-diamminedichloroplatinum(II)-induced toxicity in kidney, gut, and bone marrow by diethyldithiocarbamate. Cancer Res 46: 2751

    Google Scholar 

  10. Borch RF, Markman M (1989) Biochemical modulation of cisplatin toxicity. Pharmacol Ther 41: 371

    Google Scholar 

  11. Brillet G, Detay G, Bunker D, Ben Hmida M, Baumelou A, Jacobs C (1991) Peut-on prévenir la toxicité rénale du cisplatine. Nephrologie 12: 143

    Google Scholar 

  12. Calabro Jones PM, Aguilera JA, Ward JF (1988) Uptake of WR 2721 derivatives by cells in culture: identification of the transported form of the drug. Cancer Res 48: 3634

    Google Scholar 

  13. Chiuten D, Vogl S, Kaplan B, Camacho F (1983) Is there cumulative or delayed toxicity from cis-platinum? Cancer 52: 211

    Google Scholar 

  14. Cvitkovic E, Hayes DM, Golbey RB, Krakoff IH (1991) Cisplatin nephrotoxicity: diethyldithiocarbamate, WR 2721, or just water. J Clin Oncol 9: 707

    Google Scholar 

  15. Daley-Yates PT, McBrien DCH (1984) Cisplatin metabolites in plasma, a study of their pharmacokinetics and importance in the nephrotoxic and antitumour activity of cisplatin. Biochem Pharmacol 33: 3063

    Google Scholar 

  16. Daugaard G (1990) Cisplatin nephrotoxicity: experimental and clinical studies. Dan Med Bull 37: 1

    Google Scholar 

  17. Daugaard G, Abildgaard U (1989) Cisplatin nephrotoxicity: a review. Cancer Chemother Pharmacol 25: 1

    Google Scholar 

  18. Daugaard G, Abildgaard U, Holstein-Rathlou NH, Leyssac PP, Amtorp O, Dikhoff TG (1986) Acute effect of cisplatin on renal hemodynamics and tubular function in dog kidneys. Renal Physiol 9: 308

    Google Scholar 

  19. Daugaard G, Rossing N, Rorth M (1988) Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose treatment. Cancer Chemother Pharmacol 21: 163

    Google Scholar 

  20. Daugaard G, Abildgaard U, Holstein-Rathlou NH, Bruunshuus I, Bucher D, Leyssac PP (1988) Renal tubular function in patients treated with high-dose cisplatin. Clin Pharmacol Ther 44: 164

    Google Scholar 

  21. Daugaard G, Holstein-Rathlou NH, Leyssac PP (1988) Effect of cisplatin on proximal convoluted and straight segments of the rat kidney. J Pharmacol Exp Ther 224: 1081

    Google Scholar 

  22. Dedon PC, Borch RF (1987) Characterisation of the reactions of platinum antitumor agents with biologic and non biologic sulfur containing nucleophils. Biochem Pharmacol 36: 1955

    Google Scholar 

  23. De Gislain C, Dumas M, d'Athis P, Noudeau-Chadoint V, Tessaro P, Guerrin J (1991) Etude pharmacocinétique plasmatique et urinaire du cisdiamine dichloroplatinum en fonction de la période d'administration. Bull Cancer 6: 533

    Google Scholar 

  24. Deray G, Dubois M, Beaufils H, Cacoub P, Anouar M, Jaudon MC, Baumelou A, Jouanneau C, Jacobs C (1988) Effects of nifedipine on cisplatin-induced nephrotoxicity in rats. Clin Nephrol 30: 146

    Google Scholar 

  25. Dobyan DC, Levi J, Jacobs C, Kosek J, Weiner MW (1980) Mechanism of cis-platinum nephrotoxicity. II. Morphologic observations. J Pharmacol Exp Ther 21: 551

    Google Scholar 

  26. Dumas M, De Gislain C, d'Athis P, Chadoint-Noudeau V, Escousse A, Guerrin J, Autissier N (1990) Influence of hydration on ultrafilterable platinum kinetics and kidney function in patients treated withcis-diamminedichloroplatinum(II). Cancer Chemother Pharmacol 26: 278

    Google Scholar 

  27. Evans S (1991) Nursing measures in the prevention and treatment of renal cell damage associated with cisplatin administration. Cancer Nursing 14: 91

    Google Scholar 

  28. Felder TB, Wasserman K, Shahr Oaredes J, Hung WK, Newmann RA (1987) Effect of diethyldithiocarbamate (DDTC) and sodium thiosulfate on the cytotoxicity and pharmacology of cisplatin (abstract). Proc Am Assoc Cancer Res 28: 231

    Google Scholar 

  29. Fjeldborg P, Sorensen J, Helkjaer PE (1986) The long-term effect of cisplatin on renal function. Cancer 58: 2214

    Google Scholar 

  30. Gandara DR, Perez EA, Wiebe V, DeGregorio MW (1991) Cisplatin chemoprotection and rescue: pharmacologic modulation of toxicity. Semin Oncol 18 [Suppl 3]: 49

    Google Scholar 

  31. Glover D, Grabelsky S, Fox K, Weiler C, Cannon L, Glick J (1989) Clinical trials of WR 2721 and cis-platinum. Int J Radiat Oncol Biol Phys 16: 1201

    Google Scholar 

  32. Gonzales-Vitale JC, Hayes DM, Cvitkovic E, Sternberg SS (1977) The renal pathology in clinical trials ofcis-platinum (II) diamminedichloride. Cancer 39: 1362

    Google Scholar 

  33. Gordon JA, Gattone UH (1986) Mitochondrial alterations in cisplatinum-induced acute renal failure. Am J Physiol 250: 991

    Google Scholar 

  34. Hannemann J, Baumann K (1988) Cisplatin-induced lipid peroxidation and decrease of gluconeogenesis in rat kidney cortex: different effects of antioxidants and radical scavengers. Toxicology 51: 119

    Google Scholar 

  35. Hayes DM, Cvitkovic E, Golbey RB, Scheiner E, Helson L, Krakoff IH (1977) High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis. Cancer 39: 1372

    Google Scholar 

  36. Heidemann HT, Gerkens JF, Jakson EK, Branch RA (1985) Attenuation of cisplatinum-induced nephrotoxicity in the rat by high salt diet, furosemide, and acetazolamide. Arch Pharmacol 329: 201

    Google Scholar 

  37. Higby PJ, Wallace HS, Bebesis G (1975) Reduction ofcis-dichlorodiammineplatinum(II) (DDP). Toxicity by penicillamine compounds in animal models and humans. Am Assoc Cancer Res 16: 523

    Google Scholar 

  38. Higby PJ, Wallace HJ, Albert DJ, Holland JF (1975)cis-Diamminedichloroplatinum (NSC-119875): a phase I study. Cancer Chemother Rep 59: 647

    Google Scholar 

  39. Hilgard P, Pohl J (1990) Oxazaphosphorine toxicity reduction by mesna. Cancer Treat Rev 17: 217

    Google Scholar 

  40. Hill J, Speer RJ, Loeb E, McLellan A, Hill No, Khan A (1972) Clinical experience with cisplatinum diamminedichloride(DDP). In: Advances in antimicrobial and antineoplastic chemotherapy, vol II. Baltimore University Park Press, Baltimore, p 255

    Google Scholar 

  41. Hirosawa A, Niitani H, Hayashibara K, Tzuboi E (1989) Effects of thiosulfate in combination therapy ofcis-dichorodiammineplatinum and vindesine. Cancer Chemother Pharmacol 23: 255

    Google Scholar 

  42. Howell SB, Pfeifle CE, Wung WE, Olshen RA (1983) Intraperitonealcis-diamminedichloroplatinum with systemic thiosulfate protection. Cancer Res 43: 1426

    Google Scholar 

  43. Jacobs C, Bertino JR, Goffinet DR, Willard EF, Goode RL (1978) 24 hour infusion of cis-platinum in head and neck cancers. Cancer 42: 2135

    Google Scholar 

  44. Jacobs C, Kaubisch S, Halsey J, Lum BL, Gosland M, Coleman CN (1991) The use of probenecid as a chemoprotector against cisplatin nephrotoxicity. Cancer 67: 1518

    Google Scholar 

  45. Jacobs C, Kalman SM, Trotton M (1980) Renal handling ofcis-diamminedichloroplatinum(II). Cancer Treat Rep 64: 1223

    Google Scholar 

  46. Jones BR, Gralla RA, Mladek J (1980) Comparison of methods of evaluated nephrotoxicity of platinum. Clin Pharmacol Ther 27: 557

    Google Scholar 

  47. Kempf JR, Ivankovic S, Wiessler M, Schmal D (1985) Effective prevention of the nephrotoxicity of cisplatin (CDDP) by administration of sodium 2-mercaptoethanesulfonate (Mesna) in rats. Br J Cancer 52: 937

    Google Scholar 

  48. Koikawa Y, Uozumi J, Ueda T, Yasumasu T, Kumazawa J (1993) Prophylactic effect of methylprednisolone against cisplatin-induced nephrotoxicity in rats. Toxicol Lett 66: 281

    Google Scholar 

  49. Leeuwenkamp OR, Van Der Vijgh WJF, Neijt JP, Pinedo HM (1990) Reaction kinetics of cisplatin and its monoaquated species with the (potential) renal protecting agents (di)mesna and thiosulfate. Estimation of the effect of protecting agents on the plasma and peritoneal AUCs of CDDP. Cancer Chemother Pharmacol 27: 111

    Google Scholar 

  50. Lehane D, Winston A, Gray R, Daskal Y (1979) The effect of diuretic pre-treatment on clinical morphological and ultrastructural cis-platinum-induced nephrotoxicity. Int J Radiat Oncol Biol Phys 5: 1393

    Google Scholar 

  51. Levi FA, Hrushesky WJM, Blomquist CH, Lakatua DJ, Haus E, Halberg F, Kennedy BJ (1982) Reduction in thecis-diamminedichloroplatinum nephrotoxicity in rats by optimal circadian drug timing. Cancer Res 42: 950

    Google Scholar 

  52. Levi J, Jacobs C, Kalman SM, McTigue M, Weiner MW (1980) Mechanism of cis-platinum nephrotoxicity. I. Effects of sulfhydryl groups in rat kidneys. J Pharmacol Exp Ther 213: 543

    Google Scholar 

  53. Leyland-Jones B, Morrow C, Tate S, Urmacher C, Gordon C, Young CW (1983)cis-Diamminedichloroplatinum(II) nephrotoxicity and its relationship to renal gamma-glutamyl transpeptidase and glutathione. Cancer Res 43: 6072

    Google Scholar 

  54. Litterst CL (1981) Alterations in the toxicity ofcis-dichlorodiammineplatinum(II) and in tissue localization of platinum as a function of NaCl concentration in the vehicle of administration. Toxicol Appl Pharmacol 61: 99

    Google Scholar 

  55. Madias NE, Harrington JT (1978) Platinum nephrotoxicity. Am J Med 65: 307

    Google Scholar 

  56. McClay EF, Howell SB (1990) A review: i.p. cisplatin in the management of patients with ovarian cancer. Gynecol Oncol 36: 1

    Google Scholar 

  57. Merin CE (1979) Treatment of genitourinary tumors withcis-dichlorodiammineplatinum(II): experience in 250 patients. Cancer Treat Rep 63: 1579

    Google Scholar 

  58. Nagamuma A, Satoh M, Imura N (1987) Prevention of lethal and renal toxicity ofcis-diamminedichloroplatinum(II) by induction of metallothionein synthesis without compromising its antitumor activity in mice. Cancer Res 47: 983

    Google Scholar 

  59. Offerman JJG, Meijer S, Sleijfer DTH, Mulder NH, Donker AJM, Schrafford Koops H, Van Der Hem GK (1984) Acute effects ofcis-diamminedichloroplatinum (CDDP) on renal function. Cancer Chemother Pharmacol 12: 36

    Google Scholar 

  60. Offerman JJG, Sleijfer DT, Mulder NH, Meijer S, Schrafford Koops H, Donker AJM (1985) The effect of captopril on renal function in patients during the firstcis-diamminedichloroplatinum(II) infusion. Cancer Chemother Pharmacol 14: 262

    Google Scholar 

  61. Oriana S, Böhm S, Spatti GB, Zunino F, Di Re F (1987) A preliminary clinical experience with reduced glutathione as protector against cisplatin-toxicity. Tumori 73: 337

    Google Scholar 

  62. Ostrow S, Ergorin MJ, Haln D, Markus S, Aisner J, Chang P, Leroy A, Bachur NR, Wienick PH (1981) High dose cisplatin therapy using mannitol versus furosemide. Diuresis comparative pharmacokinetics and toxicity. Cancer Treat Rep 65: 73

    Google Scholar 

  63. Ozols RF, Corden BJ, Jacob J, Wesley MN, Ostchega Y, Young RC (1984) High-dose cisplatin in hypertonic saline. Ann Intern Med 100: 19

    Google Scholar 

  64. Paredes J, Hong WK, Felder JB, Dimery IW, Choksi AJ, Newman RA, Castellanos AM, Robbins KT, McCarthy K, Atkinson N, Kramer AM, Hersh EM, Goepfert H (1988) Prospective randomized trial of high-dose cisplatinum and fluorouracil infusion with or without sodium diethyldithiocarbamate in recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 6: 955

    Google Scholar 

  65. Pera MF, Zook BC, Harder HC (1979) Effects of mannitol or furosemide diuresis on the nephrotoxicity and physiological disposition ofcis-dichlorodiammineplatinum(II) in rats. Cancer Res 39: 1269

    Google Scholar 

  66. Perez Soler R, Khokhar AR (1992) Lipophilic cisplatin analogues entrapped in liposomes: role of intraliposomal drug activation in biological activity. Cancer Res 52: 6341

    Google Scholar 

  67. Pfeifle CE, Howell SB, Felthouse RD, Woliver TBS, Andrews PA, Markman M, Murphy MP (1985) High-dose cisplatin with sodium thiosulfate protection. J Clin Oncol 3: 237

    Google Scholar 

  68. Qasi R, Chang AYC, Borch RF, Montine T, Dedon P, Loughner J (1988) Phase I clinical and pharmacokinetic study of diethyldithiocarbamate as a protector from toxic effects of cisplatin. J Natl Cancer Inst 80: 1486

    Google Scholar 

  69. Rosenberg B (1985) Fundamental studies with cisplatin. Cancer 55: 2304

    Google Scholar 

  70. Rosenberg B, Van Camp L, Krigas T (1965) Inhibition of cell division inEscherichia coli by electrolysis products from a platinum electrode. Nature 205: 698

    Google Scholar 

  71. Ross DA, Gale GR (1979) Reduction in the renal toxicity ofcis-dichlorodiammineplatinum(II) by probenecid. Cancer Treat Rep 63: 781

    Google Scholar 

  72. Safirstein R, Miller P, Guttenplan JB (1984) Uptake and metabolism of cisplatin by rat kidney. Kidney Int 25: 228

    Google Scholar 

  73. Safirstein R, Winston J, Moel D, Dikman S, Guttenplan J (1987) Cisplatin nephrotoxicity: insights into mechanism. Int J Androl 10: 325

    Google Scholar 

  74. Salem P, Khalyl M, Jabboury K, Hashimi L (1984)cis-Diamminedichloroplatinum(II) by 5-day continuous infusion: a new dose schedule with minimal toxicity. Cancer 53: 837

    Google Scholar 

  75. Satoh M, Naganuma A, Imura N (1988) Metallothionein induction prevents toxic side effects of cisplatin and adriamycin used in combination. Cancer Chemother Pharmacol 21: 176

    Google Scholar 

  76. Satoh M, Kloth DM, Kadhim SA, Chin JL, Naganuma A, Imura N, Cherian MG (1993) Modulation of both cisplatin nephrotoxicity and drug resistance in murine bladder tumor by controlling metallothionein synthesis. Cancer Res 53: 1829

    Google Scholar 

  77. Schilsky RL, Anderson T (1979) Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin. Ann Intern Med 90: 929

    Google Scholar 

  78. Schroyens WA, Meeker JB, Dodion P, Stryckmans PA, Rozencweig M (1988) Comparative effect of cisplatin, spiroplatin, carboplatin, iproplatin and JM 40 in a human myeloid clonogenic assay. Eur J Cancer Clin Oncol 24: 1309

    Google Scholar 

  79. Sleijfer DT, Offerman JJG, Mulder NH, Verweij M, Van Der Hem GK, Schraffordt Koops H, Meijer S (1987) The protective potential of the combination of verapamil and cimetidine on cisplatin-induced nephrotoxicity in man. Cancer 60: 2823

    Google Scholar 

  80. Sobrego A, Guglielmi A, Aschele C, Rosso R (1990) Current strategies to reduce cisplatin toxicity. J Chemother 2: 3

    Google Scholar 

  81. Sommer S, Thorling EB, Jacobsen A, Steiness E, Ostergaar K (1989) Can bismuth decrease the kidney toxic effect of cis-platinum? Eur J Cancer Clin Oncol 25: 1903

    Google Scholar 

  82. Tedeschi M, Böhm S, Dire F, Oriana S, Spatti GB, Tognella S, Zunino F (1990) Glutathione and detoxification. Cancer Treat Rev 17: 203

    Google Scholar 

  83. Tognella S (1990) Pharmacological interventions to reduce platinum-induced toxicity. Cancer Treat Rev 17: 139

    Google Scholar 

  84. Treskes M, Boven E, Holwerda V, Pinedo M, Wim JF (1992) Time-dependence in the selective modulation of cisplatin-induced nephrotoxicity by WR-2721 in the mouse. Cancer Res 52: 2257

    Google Scholar 

  85. Umeki S, Watanabe M, Yagi S, Soejima R (1988) Supplemental fosfomycin and/or steroids that reduce cisplatin-induced nephrotoxicity. Am J Med Sci 295: 6

    Google Scholar 

  86. Umeki S, Tsukiyama K, Ukimoto N, Soejima R (1989) Urinastatin (Kunitz type proteinase inhibitor) reducing cisplatin nephrotoxicity. Am J Med Sci 298: 221

    Google Scholar 

  87. Uozumi J, Litterst CL (1986) Antagonizing action of sodium thiosulfate against cisplatin in vitro and in vivo (abstract). Proc Am Assoc Cancer Res 27: 287

    Google Scholar 

  88. Uozumi J, Ueda T, Yasumasu T, Koikawa Y, Kumazawa J (1992) Calcium blockers enhance cisplatin-induced nephrotoxicity in rats. Int Urol Nephrol 24: 549

    Google Scholar 

  89. Verrij LR, Smolders IJH, Bosnie N, Begg AC (1992) Reduction in the systemic exposure and toxicity of cisplatin by encapsulation in poly-lactide-co-glycolide. Cancer Res 52: 6653

    Google Scholar 

  90. Yuhas JM (1980) Active versus passive absorption kinetics as the basis for selective protection of normal tissues by WR S-2-(3-aminopropylamino)-ethylphosphorothioic acid. Cancer Res 40: 1519

    Google Scholar 

  91. Zunino F, Pratesi G, Micheloni A, Cavalletti E, Sala F, tofanetti O (1989) Protective effect of reduced glutathione against cisplatin-induced renal and systemic toxicity and its influence on the therapeutic activity of the antitumor drug. Chem Biol Interact 70: 89

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Médecine A — Pneumologie, CHU Gaston Doumergue, F-3006, Nîmes Cedex, France

    Véronique Pinzani, Inger Johanne Haug & Pierre Balmès

  2. Laboratoire de Pharmacocinétique, Faculté de Pharmacie, F-34060, Montpellier Cedex 01, France

    Françoise Bressolle

  3. Pharmacie, CHU Gaston Doumergue, F-30006, Nîmes Cedex, France

    Marc Galtier

  4. Centre Régional de Pharmacovigilance, CHU Saint Charles, 300 rue Auguste Broussonnet, F-34295, Montpellier Cedex 5, France

    Véronique Pinzani, Inger Johanne Haug & Jean Pierre Blayac

Authors
  1. Véronique Pinzani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Françoise Bressolle
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Inger Johanne Haug
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marc Galtier
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jean Pierre Blayac
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Pierre Balmès
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pinzani, V., Bressolle, F., Johanne Haug, I. et al. Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review. Cancer Chemother. Pharmacol. 35, 1–9 (1994). https://doi.org/10.1007/BF00686277

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00686277

Key words

Search

Navigation